Genmab A/S
GMAB
#1144
Rank
$20.744 B
Marketcap
Denmark
Country
$33.75
Share price
9.40%
Change (1 day)
21.62%
Change (1 year)
Categories
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with…
Key Metrics
Trailing P/E
27.11
Forward P/E
21.65
EPS (TTM)
$1.27
Forward EPS
$1.59
Price / Book
3.45
EV / EBITDA
17.5x
Beta
0.70
Dividend Yield
—
Return on Equity
14.00%
Return on Assets
8.79%
Debt / Equity
88.52
Current Ratio
2.46
Gross Margin
93.03%
Operating Margin
35.24%
Net Profit Margin
19.07%
Free Cash Flow
$870.625M
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 17 – Sep 16
+4.84%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$3.720B
Latest Net Income$963.000M
Reporting periods3
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Genmab A/S with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
GMAB
No recent news available. Set FINNHUB_API_KEY to enable news.
